Current status of in vivo bioanalysis of nano drug delivery systems
The development of nano drug delivery systems (NDDSs) provides new approaches to fighting against diseases. The NDDSs are specially designed to serve as carriers for the delivery of active pharmaceutical ingredients (APIs) to their target sites, which would certainly extend the benefit of their uniq...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2020-06-01
|
Series: | Journal of Pharmaceutical Analysis |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2095177919311724 |
id |
doaj-a6ed703d467d4c9a8a278e8cdc6c587b |
---|---|
record_format |
Article |
spelling |
doaj-a6ed703d467d4c9a8a278e8cdc6c587b2021-04-02T13:43:26ZengElsevierJournal of Pharmaceutical Analysis2095-17792020-06-01103221232Current status of in vivo bioanalysis of nano drug delivery systemsTingting Wang0Di Zhang1Dong Sun2Jingkai Gu3Clinical Laboratory, The First Hospital, Jilin University, Changchun, 130061, PR China; Research Center for Drug Metabolism, College of Life Science, Jilin University, Changchun, 130012, PR ChinaResearch Center for Drug Metabolism, College of Life Science, Jilin University, Changchun, 130012, PR ChinaDepartment of Biopharmacy, College of Life Science, Jilin University, Changchun, 130012, PR China; Key Laboratory of Molecular Pharmacology and Drug Evaluation, Ministry of Education, Yantai University, Yantai, 264005, PR China; Corresponding author. Department of Biopharmacy, College of Life Science, Jilin University, Changchun, 130012, PR China.Research Institute of Translational Medicine, The First Hospital, Jilin University, Changchun, 130061, PR China; Research Center for Drug Metabolism, College of Life Science, Jilin University, Changchun, 130012, PR China; Corresponding author. Research Institute of Translational Medicine, the First Hospital, Jilin University, Changchun, 130061, PR China.The development of nano drug delivery systems (NDDSs) provides new approaches to fighting against diseases. The NDDSs are specially designed to serve as carriers for the delivery of active pharmaceutical ingredients (APIs) to their target sites, which would certainly extend the benefit of their unique physicochemical characteristics, such as prolonged circulation time, improved targeting and avoiding of drug-resistance. Despite the remarkable progress achieved over the last three decades, the understanding of the relationships between the in vivo pharmacokinetics of NDDSs and their safety profiles is insufficient. Analysis of NDDSs is far more complicated than the monitoring of small molecular drugs in terms of structure, composition and aggregation state, whereby almost all of the conventional techniques are inadequate for accurate profiling their pharmacokinetic behavior in vivo. Herein, the advanced bioanalysis for tracing the in vivo fate of NDDSs is summarized, including liquid chromatography tandem-mass spectrometry (LC-MS/MS), Förster resonance energy transfer (FRET), aggregation-caused quenching (ACQ) fluorophore, aggregation-induced emission (AIE) fluorophores, enzyme-linked immunosorbent assay (ELISA), magnetic resonance imaging (MRI), radiolabeling, fluorescence spectroscopy, laser ablation inductively coupled plasma MS (LA-ICP-MS), and size-exclusion chromatography (SEC). Based on these technologies, a comprehensive survey of monitoring the dynamic changes of NDDSs in structure, composition and existing form in system (i.e. carrier polymers, released and encapsulated drug) with recent progress is provided. We hope that this review will be helpful in appropriate application methodology for investigating the pharmacokinetics and evaluating the efficacy and safety profiles of NDDSs.http://www.sciencedirect.com/science/article/pii/S2095177919311724NDDSsPolymerMethodologyPharmacokineticsRelease |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Tingting Wang Di Zhang Dong Sun Jingkai Gu |
spellingShingle |
Tingting Wang Di Zhang Dong Sun Jingkai Gu Current status of in vivo bioanalysis of nano drug delivery systems Journal of Pharmaceutical Analysis NDDSs Polymer Methodology Pharmacokinetics Release |
author_facet |
Tingting Wang Di Zhang Dong Sun Jingkai Gu |
author_sort |
Tingting Wang |
title |
Current status of in vivo bioanalysis of nano drug delivery systems |
title_short |
Current status of in vivo bioanalysis of nano drug delivery systems |
title_full |
Current status of in vivo bioanalysis of nano drug delivery systems |
title_fullStr |
Current status of in vivo bioanalysis of nano drug delivery systems |
title_full_unstemmed |
Current status of in vivo bioanalysis of nano drug delivery systems |
title_sort |
current status of in vivo bioanalysis of nano drug delivery systems |
publisher |
Elsevier |
series |
Journal of Pharmaceutical Analysis |
issn |
2095-1779 |
publishDate |
2020-06-01 |
description |
The development of nano drug delivery systems (NDDSs) provides new approaches to fighting against diseases. The NDDSs are specially designed to serve as carriers for the delivery of active pharmaceutical ingredients (APIs) to their target sites, which would certainly extend the benefit of their unique physicochemical characteristics, such as prolonged circulation time, improved targeting and avoiding of drug-resistance. Despite the remarkable progress achieved over the last three decades, the understanding of the relationships between the in vivo pharmacokinetics of NDDSs and their safety profiles is insufficient. Analysis of NDDSs is far more complicated than the monitoring of small molecular drugs in terms of structure, composition and aggregation state, whereby almost all of the conventional techniques are inadequate for accurate profiling their pharmacokinetic behavior in vivo. Herein, the advanced bioanalysis for tracing the in vivo fate of NDDSs is summarized, including liquid chromatography tandem-mass spectrometry (LC-MS/MS), Förster resonance energy transfer (FRET), aggregation-caused quenching (ACQ) fluorophore, aggregation-induced emission (AIE) fluorophores, enzyme-linked immunosorbent assay (ELISA), magnetic resonance imaging (MRI), radiolabeling, fluorescence spectroscopy, laser ablation inductively coupled plasma MS (LA-ICP-MS), and size-exclusion chromatography (SEC). Based on these technologies, a comprehensive survey of monitoring the dynamic changes of NDDSs in structure, composition and existing form in system (i.e. carrier polymers, released and encapsulated drug) with recent progress is provided. We hope that this review will be helpful in appropriate application methodology for investigating the pharmacokinetics and evaluating the efficacy and safety profiles of NDDSs. |
topic |
NDDSs Polymer Methodology Pharmacokinetics Release |
url |
http://www.sciencedirect.com/science/article/pii/S2095177919311724 |
work_keys_str_mv |
AT tingtingwang currentstatusofinvivobioanalysisofnanodrugdeliverysystems AT dizhang currentstatusofinvivobioanalysisofnanodrugdeliverysystems AT dongsun currentstatusofinvivobioanalysisofnanodrugdeliverysystems AT jingkaigu currentstatusofinvivobioanalysisofnanodrugdeliverysystems |
_version_ |
1721564064580108288 |